НАНаталья Александровна Алпатова

Наталья Александровна Алпатова


Наталья Александровна Алпатова has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validation of an in vitro biological method for filgrastim potency assessment

    by L. A. Gaiderova, M. L. Baykova, O. V. Golovinskaya, S. L. Lysikova, V. V. Fomenko, N. A. Alpatova

    INTRODUCTION. Filgrastim is a human granulocyte colony-stimulating factor produced using recombinant DNA technology. Since filgrastim quality control necessitates a validated method, establishing the entire method validation parameters is of high priority; confirming the previously established parameters gains primary importance when substituting critical reagents/ materials/parameters. AIM. This study aimed to select and confirm a number of validation parameters for in vitro biological method that would assess filgrastim potency using NFS-60 cell line. MATERIALS AND METHODS. Filgrastim potency was assessed by fluorescence intensity of alamarBlue™ reagent at excitation wavelengths of 530 nm and emission of 620 nm directly proportional to proliferation level of NFS-60 cells exposed to filgrastim 0.1 to 208 IU/mL. Statistical analysis of the results was performed using the 4-parameter logistic function 4PL and the parallel line analysis in PLA 2.0.0 software. RESULTS. The method was deemed precise: the coefficient of variation (CV) in the repeatability study was 6.20%, and the intermediate precision study showed CV 1.19% (acceptance criterion CV≤25%). The method was linear; the coefficient of determination for the linear function was R 2=0.99 (acceptance criterion R 2≥0.95). The degree of recovery was 101.6% and did not exceed ±10% of the expected value. The method was robust to an increased density of the cell suspension from 1.5×105 to 3.0×105 cells/mL (CV=0.07%) and to prolonged incubation of filgrastim samples with the cell suspension (from 48 to 72 h, CV=4.2%) or with fluorescent dye (from 4 to 6 h, CV=2.05%). CONCLUSIONS. The in vitro method assessing specific potency of filgrastim-based preparations using NFS-60 cell line is linear, precise, and accurate, and has proven to be stable under controlled changes of certain parameters. Confirmed applicability of NFS-60 cell line for assessing the potency of filgrastim-based preparations is essential for manufacturers, since it expands the range of cell cultures used for quality assessment of preparations.

  • Open Access

    Implementation of the 3Rs Concept in Quality Control of Biologicals: Status and Prospects (Review)

    by L. A. Gaiderova, N. A. Alpatova, O. V. Golovinskaya, А. М. Гуськов, E. K. Lipatova, M. N. Lavrova

    INTRODUCTION. Many countries are implementing an increasing number of alternatives to animal testing in the research, development, and quality control of medicines under the concept of 3Rs (replacement, reduction, and refinement). However, the implementation of in vitro alternatives to in vivo methods into batch release testing of biologicals, primarily vaccines, is a challenging process. The introduction of the 3Rs principles into regulatory and industry standards requires a comprehensive analysis, including, among other things, a study of specific considerations for national frameworks.AIM. This study aimed to analyse the degree of global integration of the 3Rs principles in the quality control of biological medicinal products and to assess existing challenges and opportunities for a successful transition to non-animal quality control methods in the Russian Federation.DISCUSSION. The key advantages of in vitro biological methods over in vivo approaches for quality control of medicinal products include reduced variability, higher specificity, and shorter testing timelines. Analysis of assessments by regulatory authorities and pharmaceutical manufacturers regarding the opportunities and challenges in implementing the 3Rs principles has identified the following main arguments for replacing in vivo methods: ethical considerations, relevance of reducing testing time, decreased variability. The integration of in vitro methods is hindered by insufficient information on alternative approaches and the lack of harmonised regulatory frameworks for adopting 3Rs principles. For instance, the European Pharmacopoeia has eliminated all general safety testing of biological medicinal products in animals as part of its 3Rs implementation. Furthermore, the World Health Organization has developed guidelines for the phased discontinuation of animal testing in the quality control of biological products.CONCLUSIONS. The main challenges associated with 3Rs implementation include the difficulty of confirming the in vitro – in vivo correlation (particularly, by comparing in vivo and in vitro methods), the lack of regulatory harmonisation, and the insufficient regulatory support for manufacturers in adopting alternative methods. The international harmonisation of regulatory requirements is necessary to effectively address these issues and successfully implement the 3Rs principles in the quality control procedures for biologicals released in different countries, including the Russian Federation.


  • Open Access

    Expert Assessment of In Vitro Potency Assays for Monoclonal Antibody Preparations

    by N. A. Alpatova, O. V. Golovinskaya, M. L. Baykova, S. L. Lysikova, L. A. Gaiderova

    INTRODUCTION. The quality control of biotechnological medicinal products requires a range of biological assay procedures. The development of bioassays for potency determination is a complex process that should comply with the requirements set forth in regulatory standards. For adequate reproducibility, bioassays should be properly described in draft product specification files.AIM. This study aimed to summarise the recommendations for developing in vitro bioassays for potency determination of monoclonal antibody preparations and for describing these bioassays in product specification files.DISCUSSION. This article describes the Fab- and Fc-associated biological activi­ty mechanisms of monospecific and bispecific monoclonal antibodies. The article covers in vivo and in vitro methods used to study these mechanisms, with emphasis on the reporter gene assay. The article formulates the concept and analyses the components of a holistic analytical system that is necessary for bioassay development. A well-designed analytical procedure can minimise the influence of critical factors on the test results and reduce the risks of both random and systematic errors. This article presents an estimation of the significance of detailed description of critical procedure parameters in the draft product specification file for a monoclonal antibody.CONCLUSIONS. A bioassay for the determination of potency should reflect the mecha­nism of action of the medicinal product and should provide the lowest possible variability and the highest possible ease of use. An adequate analytical procedure with appropriate analytical conditions can reduce the risk of obtaining invalid quality control results.

  • Open Access

    Potency evaluation of erythropoietin products: current status

    by L. A. Gaiderova, N. A. Alpatova, S. L. Lysikova, А. М. Гуськов, O. V. Golovinskaya

    INTRODUCTION. Given the widespread clinical use of recombinant human erythropoietin (rhEPO) products from different manufacturers, potency assays should ensure that patients receive comparable doses of rhEPO across medicinal products. The harmonisation of approaches to potency testing requires the use of pharmacopoeial bioassays and appropriate international/pharmacopoeial reference standards (RSs).AIM. This study aimed to summarise information on pharmacopoeial requirements, relevant RSs, and bioassays (in vivo and in vitro) for the assessment of rhEPO potency, as well as to analyse the pharmacopoeial compliance of manufacturers’ specifications for rhEPO products authorised in Russia.DISCUSSION. This article presents information on the molecular structure of erythropoietin. The glycosylation profile of erythropoietin not only accounts for most of the differences in the half-life and biodegradation rate but also significantly influences the potency of rhEPO products. The authors outlined the pharmacopoeial requirements for potency assays in vivo, summarised the information on RSs for potency determination, characterised the development of potency assays in vitro, and studied the possibility of including in vitro assays in pharmacopoeias. The analysis showed that some potency assays used for rhEPO products manufactured in Russia did not comply with the requirements of the State Pharmacopoeia of the Russian Federation.CONCLUSIONS. The study identified the need to develop and certify a national pharmacopoeial RS for the potency of rhEPO in order to satisfy the demands of Russian manufacturers in the context of import substitution. To implement adequate 3R-compliant methods for rhEPO quality assessment, it is necessary to harmonise approaches to potency testing of rhEPO products and develop a consolidated document governing such testing.

  • Open Access

    Studies on the immunogenicity of therapeutic proteins: methodological aspects of identifying and studying of the anti-drug antibodies

    by Zh.I. Avdeeva, A.A. Soldatov, N.A. Alpatova, V.P. Bondarev, V.D. Mosyagin, A.S. Korovkin, V.A. Merkulov

    Исследования иммуногенности терапевтических белков: методические аспекты выявления и изучения антител к лекарственному препарату


  • Open Access

    International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update

    by L. A. Gayderova, N. A. Alpatova, S. L. Lysikova, M. L. Baykova, А. М. Гуськов, D. A. Zubkov

    Scientific relevance. The clinical effects and the expiration of patents for original (reference) biotechnological medicines based on monoclonal antibodies (mAbs) stimulated the development of biosimilar mAbs. The quality profile of a biosimilar mAb should correspond to the quality of the reference medicinal product. When demonstrating biosimilarity and determining the activity of medicines as part of batch quality control, analysts should study the biological properties of mAbs using suitable reference standards. The lack of international standards (ISs) makes mAb manufacturers use in-house reference standards. There is a risk of obtaining non-uniform quality and efficacy data because of the use of in-house reference standards, the heterogeneity and structural complexity of mAbs, and the relationship between the biological activity and efficacy of mAbs.Aim. This study aimed to analyse the relevance of and need for ISs for the biological activity of biotherapeutic mAbs and to define the role of reference medicinal products and ISs in assessing biosimilarity and testing medicines throughout their lifecycle.Discussion. This review covers the issues arising from the lack of ISs for assessing the biological activity of mAbs and the role and significance of reference products and ISs for biosimilars. The authors describe the specifics of studying the biological properties of mAbs and summarise the data on the need to develop and use ISs for the standardisation of biological tests. This review presents the results of studies on the first ISs established by the World Health Organisation to assess the biological activity of mAbs; these results suggest the need to standardise mAbs using ISs to ensure the quality, safety, and efficacy of mAb therapy.Conclusions. The use of ISs for mAbs plays a key role in harmonising biological activity assessments. Publicly available ISs serve as primary standards for the calibration of secondary reference materials. Moreover, ISs are required for the harmonisation of activity evaluation (in IU) between laboratories and for the consistency of the activity of various medicinal products from different manufacturers that share the same INN. The use of ISs by mAb manufacturers will contribute to ensuring the quality of mAbs and clinical monitoring of the effectiveness of their use.


  • Open Access

    General characteristics of adjuvants and their mechanisms of action (part 2)

    by N. А. Alpatova, Zh. I. Avdeeva, S. L. Lysikova, O. V. Golovinskaya, L. A. Gayderova, V. P. Bondarev

    One of the major public health challenges today is development of new vaccines and technologies to optimize the vaccination process. There is a growing scientific interest in vaccine adjuvants that enhance vaccine immunogenicity. At present, numerous studies are underway to develop COVID-19 vaccines, including inactivated and subunit vaccines which contain adjuvants for efficient induction of immune response and solid immunity. The aim of the study was to systematise literature related to the analysis of the structure, mechanisms of action and stimulating properties of vaccine adjuvants (synthetic oligodeoxynucleotides, virosomes, polyoxidonium, sovidone), as well as to summarise data on the effects of adjuvants used in SARS-CoV, MERS-CoV, and SARS-CoV-2 vaccine development studies. The paper analyses the prospects for enhancing the stimulating effect of the adjuvants when used in combination with compounds having a different mechanism of action. It also analyses the results of studies of adjuvanted vaccines against SARS-CoV and MERS-CoV, which may be useful when selecting adjuvants with optimal efficacy and safety profiles to be used in SARS-CoV-2 vaccines under development. It was concluded that understanding of the mechanisms of action of adjuvants that mediate their stimulating effect on the body’s immune system will contribute to safe and effective use of adjuvants to enhance the immunogenicity of both authorised and new vaccines.


  • Analysis of the mechanisms of development of the immune response in hepatitis B virus infection and ways to improve the effectiveness of vaccination

    by Zh.I. Avdeeva, N.A. Alpatova, S.L. Lysikova, L.A. Gayderova, V.P. Bondarev

    Анализ механизмов развития иммунного ответа при инфицировании вирусом гепатита В и способы повышения эффективности вакцинации


  • Open Access

    General Characteristics of Adjuvants and Their Mechanism of Action (Part 1)

    by N. A. Alpatova, Zh. I. Avdeeva, S. L. Lysikova, O. V. Golovinskaya, L. A. Gayderova

    One of priority issues of the present-day healthcare system is development of new vaccines and improvement of existing ones due to decreasing immunocompetence of the population, emergence of new infections and reemergence of old ones which were previously thought to be under control. Adjuvants have proven to be integral and important components of modern vaccines, as they enhance immune response to the vaccine antigen. However, despite a lot of effort put into their development, only a small number of adjuvants are currently used in clinical practice.The aim of the study was to systematise literature data on the adjuvants’ mechanisms of action, their specific structure, composition, and stimulation effects that mediate their immunoadjuvant properties. The paper summarises data on adjuvants used as components in licensed vaccines, describes their characteristics, analyses molecular mechanisms of their action in order to establish correlation between their structure and activity, which is important for the development of more efficacious and safe adjuvants. The paper cites advanced developments aimed at enhancing stimulation effects of existing adjuvants. It concludes by stating that the key research area aimed at improving vaccination efficacy is the study of mechanisms that contribute to the development of effective protection against infectious agents, as well as analysis of how to use adjuvants to stimulate the body’s defensive mechanisms, primarily by impacting the innate immunity.


  • Open Access

    Comparative Analysis of Dyes Used in the Assessment of Filgrastim Products Specific Activity by Biological in vitro Methods

    by O. V. Golovinskaya, M. L. Baykova, N. A. Alpatova, D. A. Zubkov, V. V. Fomenko, L. A. Gayderova

    Assessment of specific activity of Russian and foreign-made filgrastim products by biological in vitro methods is performed using different types of dyes. It is important to choose one cell staining dye in order to align the procedure of filgrastim specific activity assessment using cell culture. The aim of this study was to perform comparative assessment of tetrazolium and resazurin dyes in tests determining filgrastim ability to activate proliferation of sensitive cells. Materials and methods: NFS-60 (mouse myelogenous leukemia) cell line, 2nd International Standard for Granulocyte Colony Stimulating Factor (IS), as well as МТТ, MTS, WST-1, and alamarBlue dyes were used in the study. Proliferative activity of cells was assessed in vitro. The level of cell proliferation was assessed by fluorescence or absorbance intensity. Origin Pro 9.1. and Microsoft Excel applications were used for statistical processing of the obtained results. Results: the paper compares characteristics of the most widely used dyes. It describes the procedure for choosing optimal test conditions for some of the studied dyes. The authors analysed the potential of some factors, such as duration of cell suspension incubation with IS and with a dye, composition of the lysis buffer (for MTT staining), and different readout modes, to influence the final results. Despite the fact that all the studied dyes gave reproducible dose–response curves under the given test conditions, 50% effective concentrations showed no statistically significant differences in tests with only three dyes: МТТ, MTS, and alamarBlue (р > 0.05). Conclusions: better reproducibility of results was obtained in tests using МТТ and alamarBlue. The test procedure using alamarBlue is easier to perform and less time-consuming, it does not include the cell lysis stage and does not require additional reagents, therefore this dye may be recommended for harmonisation of the test procedure to be elaborated for the Russian Pharmacopoeia.